Posted by Michael Wonder on 18 Jul 2025
Outcome statement - June 2025 DUSC meeting
18 July 2025 - The outcome statement from the June 2025 DUSC meeting is now available.
The DUSC reviewed the following technologies:
- Atezolizumab for patients with liver cancer
- Cemiplimab for patients with squamous cell carcinoma
- Nivolumab for patients with gastric cancer
- Nusinersen sodium for adults with spinal muscular atrophy
